Current guidelines in defining therapeutic strategies

Hematology/Oncology Clinics of North America

Volumn 18, Issue 4, 2004, Pages 881-893

  Ferrajoli, Alessandra ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER CENTER; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; FEVER; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTOSIS; LYMPHOCYTE; LYMPHOCYTOSIS; MINIMAL RESIDUAL DISEASE; NEUTROPHIL; NIGHT SWEAT; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; THROMBOCYTE; WEIGHT REDUCTION;

GUIDELINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM STAGING; UNITED STATES;

EID: 4344638367     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.04.006     Document Type: Review

References (44)

1. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:1996;4990-4997
2. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood. 46:1975;219-234
3. Binet J.L., Lepoprier M., Dighiero G., Charron D., D'Athis P., Vaugier G., et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 40:1977;855-864
4. Robertson L.E., Huh Y.O., Butler J.J., Pugh W.C., Hirsch-Ginsberg C., Stass S., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 80:1992;29-36
5. Provan D., Bartlett-Pandite L., Zwicky C., Neuberg D., Maddocks A., Corradini P., et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 88:1996;2228-2235
6. Esteve J., Villamor N., Colomer D., Cervantes F., Campo E., Carreras E., et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 15:2001;445-451
7. Rawstron A.C., Kennedy B., Evans P.A., Davies F.E., Richards S.J., Haynes A.P., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 98:2001;29-35
8. Gribben J.G. Monitoring disease in lymphoma and CLL patients using molecular techniques. Best Pract Res Clin Haematol. 15:2002;179-195
9. Pfitzner T., Reiser M., Barth S., Borchmann P., Schulz H., Schinkothe T., et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol. 81:2002;258-266
10. CLL Trialists' Collaborative Group Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 91:1999;861-868
11. Thomas D.A., Giles F.J., Cortes J., Faderl S., Kantarjian H., Lerner F., et al. Single agent Rituxan in early stage Chronic Lymphocytic Leukemia (CLL). Blood. 98:2001;364a
12. Jaksic B., Brugiatelli M., Krc I., Losonczi H., Holowiecki J., Planinc-Peraica A, et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer. 79:1997;2107-2114
13. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 343:2000;1750-1757
14. The French Cooperative Group on Chronic Lymphocytic Leukemia A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood. 75:1990;1422-1425
15. Raphael B., Andersen J.W., Silber R., Oken M., Moore D., Bennett J., et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol. 9:1991;770-776
16. French Cooperative Group on Chronic Lymphocytic Leukemia Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk Lymphoma. 13:1994;449-456
17. Kimby E., Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemia of B-cell type: a randomized trial. Leuk Lymphoma. (Suppl):1991;93-96
18. Keating M.J., Scouros M., Murphy S., Kantarjian H., Hester J., McCredie K.B., et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia. 2:1988;157-164
19. Keating M.J., O'Brien S., Lerner S., Koller C., Beran M., Robertson L.E., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 92:1998;1165-1171
20. O'Brien S., Kantarjian H., Beran M., Smith T., Koller C., Estey E., et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 82:1993;1695-1700
21. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98:2001;2319-2325
22. Eichhorst B.F., Busch R., Stauch M., Kneba M., Ritgen M., Söling U., et al. Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG) [abstract #369]. Blood. 2003;102
23. Robak T., Blonski J.Z., Kasznicki M., Blasinska-Morawiec M., Krykowski E., Dmoszynska A., et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 96:2000;2723-2729
24. Yamauchi T., Nowak B.J., Keating M.J., Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 7:2001;3580-3589
25. O'Brien S.M., Kantarjian H.M., Cortes J., Beran M., Koller C.A., Giles F.J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 19:2001;1414-1420
26. Flinn I.W., Byrd J.C., Morrison C., Jamison J., Diehl L.F., Murphy T., et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 96:2000;71-75
27. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Söling U., et al. Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a phase III study of the German CLL Study Group (GCLLSG) [abstract #243]. Blood. 102:2003
28. Cazin B.F., Maloum K., Cretcil M.D., Leprette S., Travade P., Delmer A., et al. Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL: final response and follow-up in 75 patients. Blood. 102:2003
29. Hainsworth J.D. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol. 30:2003;9-15
30. Lundin J., Hagberg H., Repp R., Cavallin-Stahl E., Freden S., Juliusson G., et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 101:2003;4267-4272
31. Byrd J.C., Peterson B.L., Morrison V.A., Park K., Jacobson R., Hoke E., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101:2003;6-14
32. O'Brien S.M., Kantarjian H.M., Thomas D.A., Cortes J., Giles F.J., Wierda W.G., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 98:2003;2657-2663
33. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 343:2000;1910-1916
34. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1999;1840-1847
35. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 94:1999;1848-1854
36. Lin K., Sherrington P.D., Dennis M., Matrai Z., Cawley J.C., Pettitt A.R. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 100:2002;1404-1409
37. Tobin G., Thunberg U., Johnson A., Thorn I., Soderberg O., Hultdin M., et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 99:2002;2262-2264
38. Ibrahim S., Keating M., Do K.A., O'Brien S., Huh Y.O., Jilani I., et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 98:2001;181-186
39. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 99:2002;1023-1029
40. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 100:2002;4609-4614
41. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 348:2003;1764-1775
42. Orchard J.A., Ibbotson R.E., Davis Z., Wiestner A., Rosenwald A., Thomas P.W., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 363:2004;105-111
43. Molica S., Levato D., Dell'Olio M., Matera R., Minervini M., Dattilo A., et al. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia: implications for prognosis. Haematologica. 81:1996;428-433
44. Ferrajoli A., Keating M.J., Manshouri T., Giles F.J., Dey A., Estrov Z., et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 100:2002;1215-1219